top of page

Antheia Inks $73M Series B Financing Round

MENLO PARK, CA, Antheia, a synthetic biology company enabling next-generation plant-inspired medicines, has raised $73 million in Series B financing.

The oversubscribed round was led by Viking Global Investors and included participation from Sherpalo Ventures and Hillspire. The funds will support Antheia as it brings its first pharmaceutical compound to market and scales up the production of a number of critical active pharmaceutical ingredients (APIs) and key starting materials (KSMs).

Read more at:

bottom of page